![]() ![]() We would like to invite you to join a complimentary scientific CME Webinar: “Innovations in Diagnosis and Treatment of Heart Disease 2021“ - The Quarterly Meeting of the Preventive and Consultative Heart Center of Excellence, Smidt Heart Institute, Cedars-Sinai Medical Center, on Januat 5:00-6:30 PM, Pacific Standard Time (San Francisco, GMT – 08:00).Īsher Kimchi, MD and Daniel S. “Innovations in Diagnosis and Treatment of Heart Disease 2021“ - a WebEx Webinar on January 20, 2021 The 7th International Congress on Cardiac Problems in Pregnancy (CPP2022)Ģ8th Annual San Diego Heart Failure Symposium - Advances in the Recognition and Treatment of Heart FailureĢ6th Annual Heart Failure 2022 - Update on Diagnosis and TherapyĬontroversies & Advances In The Treatment of Cardiovascular Disease: The Twentieth in the SeriesĢ5th Annual Heart Failure 2021 - Update on Diagnosis and Therapy The International Academy of Cardiology is dedicated to the advancement of global research in cardiovascular medicine through the support of scientific meetings and publications. We observed significant differences in HS-SIC between controls and myocarditis (P = 0.0014), active rejection (P = 0.0076), and atypical chest pain or palpitations (P = 0.0014) as well as between transplant patients with active rejection and those without current or prior rejection (P = 0.031).Īn echocardiographic method can be used to characterize tissue signatures of microstructural changes across a spectrum of cardiac disease including immune-inflammatory conditions.Ĭardiac microstructure Echocardiography Myocarditis Transplant rejection.Previous Meetings Under the Auspices of the International Academy of Cardiology Among cardiac transplant recipients, HS-SIC values were 0.478 ± 0.999 for active rejection, 0.594 ± 0.091 for prior rejection, and 1.191 ± 0.442 for never rejection. The mean ± standard error of the mean of HS-SIC were: 0.668 ± 0.074 for controls, 0.552 ± 0.049 for atypical chest pain/palpitations, 0.425 ± 0.058 for myocarditis, 0.881 ± 0.129 for STEMI, 1.116 ± 0.196 for severe aortic stenosis, 0.904 ± 0.116 for acute COVID, and 0.698 ± 0.103 for amyloidosis. We used Kruskal-Wallis tests to compare HS-SIC values measured in each of the clinical populations with those in the healthy control group and compared HS-SIC values between the subgroups of cardiac transplantation rejection status.įor the total sample of N = 338, the mean age was 49.6 ± 20.9 years and 50% were women. We assessed the HS-SIC's ability to differentiate between a broader diversity of clinical groups and healthy controls. Populations included myocarditis, atypical chest pain/palpitations, STEMI, severe aortic stenosis, acute COVID infection, amyloidosis, and cardiac transplantation with acute rejection, without current rejection but with prior rejection, and with no history of rejection. We conducted a retrospective case-control study of 318 patients with distinct clinical myocardial pathologies and 20 healthy controls. We aimed to determine whether this echocardiographic texture analysis of cardiac microstructure can identify inflammatory cardiac disease in the clinical setting. We have previously developed a method of echocardiographic texture analysis, called the high-spectrum signal intensity coefficient (HS-SIC) which assesses myocardial microstructure and previously associated with myocardial fibrosis. ![]() Immune-inflammatory myocardial disease contributes to multiple chronic cardiac processes, but access to non-invasive screening is limited.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |